Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Investors Business Daily

Ozempic maker now wants to keep people from becoming obese in the first place

Novo Nordisk is investing in obesity prevention, the 'real big frontier' of weight loss.

Fortune

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Why You Should Go Overweight On Novo Nordisk Stock

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.

Barchart

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,

Investors Business Daily

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

An oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

Businessweek

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook

Novo Nordisk stock forged a new high Thursday after raising financial estimates, citing its diabetes and obesity treatments.

Investors Business Daily

Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $2.7 Billion Deal

Novo Nordisk stock popped Wednesday after the drugmaker inked a $2.7 billion deal that bolsters its diabetes and obesity treatments.

Investors Business Daily

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

The Guardian - UK

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

Novo Nordisk stock popped Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Novo Nordisk A/S replenished supplies of Ozempic, a treatment for diabetes, after social media-driven enthusiasm over the drug’s use for weight loss led to six months of shortages.

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

The Independent UK

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

Tribune News Service

New obesity drug would cost Medicare $27 billion, even with limited uptake

Covering Novo Nordisk A/S’s new obesity drug Wegovy could strain the budget of US government insurance program Medicare, according to a new analysis in the New England Journal of Medicine.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Revealed: experts who praised new ‘skinny jab’ received payments from drug maker

Novo Nordisk gave millions to obesity charities and healthcare professionals, including expert who advised Nice

Investors Business Daily

CBS '60 Minutes' Story Turns FDA Headlights On Diabetes and Weight Loss Drug Stock

Growth stock Novo Nordisk is showing strength after FDA approval of breakthrough oral drug for type 2 diabetes. Shares are in a base.

The Orange County Register

How to see Coachella bands up-close at intimate venues in Southern California

ANAHEIM, Calif. — Music fans may already have their wristbands ready for the 2023 Coachella Valley Music & Arts Festival in Indio in April, but if you’re not into making the trek to the desert or the idea of three long days in the heat no longer sounds appealing, there…

Tribune News Service

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Investors Business Daily

How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly

The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday.

Investors Business Daily

IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

Tribune News Service

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.